表紙
市場調查報告書

核醫學/放射性同位素的全球市場:成長,趨勢,及預測(2019年∼2024年)

Nuclear Medicine Radioisotopes Market - Growth, Trends And Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品編碼 661020
出版日期 內容資訊 英文 119 Pages
商品交期: 2-3個工作天內
價格
核醫學/放射性同位素的全球市場:成長,趨勢,及預測(2019年∼2024年) Nuclear Medicine Radioisotopes Market - Growth, Trends And Forecast (2020 - 2025)
出版日期: 2020年03月01日內容資訊: 英文 119 Pages
簡介

本報告提供全球核醫學/放射性同位素市場的相關調查,市場機會和趨勢,成長及阻礙因素,各放射性同位素的種類、用途、地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 簡介

  • 調查成果
  • 調查的前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 成長要素
    • 癌症及心臟疾病的發生率的上升
    • 核醫學廣泛的用途
    • SPECT及PET的用途增加
    • 患者對醫療保健的意識提高
  • 阻礙因素
    • 償付的併發症
    • 法規的問題
  • 波特的五力分析
    • 新加入廠商的威脅
    • 買主/消費者談判力
    • 供應商談判力
    • 替代產品的威脅
    • 產業內的競爭

第5章 市場區隔

  • 放射性同位素的各類型
    • 鎝-99m(Tc-99m)
    • 鉈-201(Tl-201)
    • 碘(I-123)
    • 氟-18
    • 銣-82(Rb-82)
    • 碘-131(I-131)
    • 鎦-177(Lu-177)
    • 鐳-223(Ra-223)、Alpharadin
    • 錒-225(Ac-225)
    • 其他
  • 各用途
    • 腫瘤
    • 循環系統
    • 淋巴瘤
    • 甲狀腺
    • 神經
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 其他

第6章 競爭情形

  • 企業簡介
    • Agfa-Gevaert Group
    • Cardiarc Ltd
    • Digirad Corporation
    • CMR Naviscan (Gamma Medica Inc.)
    • GE Healthcare
    • Positron Corp.
    • Segami Corporation
    • Siemens Healthcare GmBH
    • Nordion (Canada) Inc.
    • NTP Radioisotopes SOC Ltd
    • Bracco SpA
    • Cardinal Health Inc.
    • Curium

第7章 市場機會及今後趨勢

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 54625

Increasing cases of cancer and cardiac ailments are the major drivers for the nuclear medicines radioisotopes market. Nuclear medicine has a huge potential in treating cancer and cardiac diseases. Growth of medical imaging is an opportunity for the growth of the global nuclear medicine radioisotope market, as both markets are correlated. Radiopharmaceuticals are approved by the Food and Drug Administration (FDA) as either drugs or biologics. They meet the statutory definition of drugs under Section 1861(t) of the Social Security Act because they either are included in the various drug compendia or recognized by hospital medical staff as drugs. Historically, nuclear medicine has been well established as a therapeutic modality for thyroid cancer, Graves' disease, hyperthyroidism, and bone pain palliation, associated with skeletal metastasis. Hence, the broadening applications of radioisotopes are expected to propel market growth.

Key Market Trends

Oncology Segment is Expected to Exhibit Fastest Growth Rate Over the Forecast Period

Radiotherapy can be used to treat various medical conditions, especially cancer, using radiation to weaken or destroy particular targeted cells. PET, which is a precise technique, uses isotopes produced in a cyclotron. It is highly used for a clinical role in oncology, with fluorine-18 as the tracer, and is proven to be the most accurate non-invasive method of detecting and evaluating most cancers. A new field for cancer treatment is targeted alpha therapy (TAT) or alpha radio-immunotherapy, especially for the control of dispersed cancers. Nuclear medicine is proven effective in oncology in several roles, spanning the course of the disease, including the characterization of a mass, staging, restaging, and monitoring of therapeutic response. Hence, owing to these associated factors, the oncology segment is expected to exhibit the fastest growth rate.

North America captured the Largest Market Share and is Expected to Retain its Dominance

North America captured the largest market share in the nuclear medicine radioisotopes market. The United States was the largest contributor to the revenue of North America, and is expected to retain its dominance owing to the higher procedural volume and increasing adoption of the nuclear medicine isotopes for various therapeutic applications. Bone scintigraphy is the next most common nuclear medicine procedure performed in the United States, but it represents only 17% of procedures. The volume of PET procedures in the United States is approximately 1.5 million per year. Oncology accounts for more than 90% of the PET and PET/CT procedures performed, whereas cardiology and neurology account for about 4% each. Canada is the largest producer of Technetium-99m. Due to the use of Tc-99m in radiopharmaceuticals, the market is expected to grow at a tremendous rate in Canada. 80% of the nuclear medicine market is driven by Tc-99m in various diagnostic procedures and treatments. Considering these factors associated with the United States and Canada, the North American market is expected to experience accelerated growth rates and market dominance.

Competitive Landscape

There is high competition among the players of the global nuclear medicine radioisotopes market. However, this competition is not by virtue of competitive pricing or product differentiation. Additionally, big players of the pharmaceutical and biotechnology industries are leveraging their huge capital reserves to venture into this market, which is further increasing the competition. GE Healthcare,NTP Radioisotopes SOC Ltd, Nordion (Canada) Inc., Siemens Healthcare, and Positron Corp. are some of the major players in the nuclear medicine radioisotopes market.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Burden of Cancer and Cardiac Disorders
    • 4.2.2 Widening Applications of Nuclear Medicine
    • 4.2.3 Increasing SPECT and PET Applications
    • 4.2.4 Increasing Patient Awareness on Radiation and Radiation Therapy
  • 4.3 Market Restraints
    • 4.3.1 Reimbursement Complications
    • 4.3.2 Regulatory Issues
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 Type of Radioisotopes
    • 5.1.1 Technetium-99m (Tc-99m)
    • 5.1.2 Thallium-201 (Tl-201)
    • 5.1.3 Iodine (I-123)
    • 5.1.4 Fluorine-18
    • 5.1.5 Rubidium-82 (Rb-82)
    • 5.1.6 Iodine-131 (I-131)
    • 5.1.7 Lutetium-177 (Lu-177)
    • 5.1.8 Radium-223 (Ra-223) & Alpharadin
    • 5.1.9 Actinium-225 (Ac-225)
    • 5.1.10 Others
  • 5.2 Application
    • 5.2.1 Oncology
    • 5.2.2 Cardiology
    • 5.2.3 Thyroid
    • 5.2.4 Neurology
    • 5.2.5 Other Applications
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Rest of the World

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Bayer AG
    • 6.1.2 Bracco SpA
    • 6.1.3 Cardinal Health Inc
    • 6.1.4 China Isotope & Radiation Corporation (CIRC)
    • 6.1.5 Curium
    • 6.1.6 Lantheus Medical Imaging, Inc
    • 6.1.7 GE Healthcare
    • 6.1.8 NTP Radioisotopes SOC Ltd
    • 6.1.9 Fujifilm Holdings Corporation
    • 6.1.10 Sotera Health (Nordion Inc.)

7 MARKET OPPORTUNITIES AND FUTURE TRENDS